EUVIMEDEUVIMED entdecken
Crossref

Defining the Diphyllin Pharmacophore for Broad-Spectrum Antiviral V-ATPase Inhibition by Structure-Guided Scaffold Modifications

Amr Elkabbany, Laura M. Sanford, Naoaki Fujii, Patrick T. Keiser, Liying Che, Oliver Bin Hu, Sucheta Parthasarathy, Brianna Close, Zhuangyan Xu, John D. Sears, Sabian A. Martinez, Jane E. Burdick und 5 weitere

Journal of Medicinal Chemistry · 16.11.2026

DOI: 10.1021/acs.jmedchem.6c01481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.11.2026. Verfasst von Amr Elkabbany und 16 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The threat of emerging viral diseases presents a critical societal need for broad-spectrum antiviral therapeutics. A key contribution to antiviral options would be a broad-spectrum agent that can treat a wide variety of viral diseases. Vacuolar H-ATPase (V-ATPase), a host proton pump critical for endosomal acidification, serves an essential role in facilitating the entry of multiple viruses. Diphyllin, a naturally occurring V-ATPase inhibitor, displays potent antiviral activity but is limited by suboptimal drug-like properties, including selectivity and metabolic instability. Molecular modeling enabled the identification of a conserved binding site on the V-ATPase a-subunit consisting of three distinct sub-pockets. Docking analyses of ninety-five known diphyllin derivatives demonstrated that active analogs effectively occupy all three subpockets, informing a structure-based design approach. A library of novel diphyllin analogs with modifications to a single-ring system showed 50-fold increases in potency for antiviral activity against Ebola, Venezuelan equine encephalitis, and Chikungunya viruses and exhibiting improvements in metabolic stability and permeability.

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Elkabbany, A., Sanford, L. M., Fujii, N., Keiser, P. T., Che, L., Hu, O. B., Parthasarathy, S., Close, B., Xu, Z., Sears, J. D., Martinez, S. A., Burdick, J. E., Moorman, N. J., Heise, M. T., Knipp, G. T., Davey, R. A., & Davisson, V. J. (2026). Defining the Diphyllin Pharmacophore for Broad-Spectrum Antiviral V-ATPase Inhibition by Structure-Guided Scaffold Modifications. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01481

Vancouver

Elkabbany A, Sanford LM, Fujii N, Keiser PT, Che L, Hu OB, et al. Defining the Diphyllin Pharmacophore for Broad-Spectrum Antiviral V-ATPase Inhibition by Structure-Guided Scaffold Modifications. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01481

BibTeX
@article{Elkabbany2026,
  author = {Elkabbany, Amr and Sanford, Laura M. and Fujii, Naoaki and Keiser, Patrick T. and Che, Liying and Hu, Oliver Bin and Parthasarathy, Sucheta and Close, Brianna and Xu, Zhuangyan and Sears, John D. and Martinez, Sabian A. and Burdick, Jane E. and Moorman, Nathaniel J. and Heise, Mark T. and Knipp, Gregory T. and Davey, Robert A. and Davisson, Vincent Jo},
  title = {Defining the Diphyllin Pharmacophore for Broad-Spectrum Antiviral V-ATPase Inhibition by Structure-Guided Scaffold Modifications},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01481}
}
Kostenlos starten →